Changes

The HPV vaccine protects against types 6, 11, 16 and 18 of the human papillomavirus (HPV), which are sexually transmitted diseases.  These strains of HPV have been associated with 70% of cervical cancer cases and may also play a role in the development of other types of cancer <ref>[http://www.cancer.gov/cancertopics/factsheet/Risk/HPV]</ref>. In June 2006, the U.S. Food and Drug Administration approved the first HPV vaccine based on observance of elevated [[antibody]] levels in a few thousand patients who had received the vaccine (including perhaps only a few hundred or less young girls).

The HPV vaccine protects against types 6, 11, 16 and 18 of the human papillomavirus (HPV), which are sexually transmitted diseases.  These strains of HPV have been associated with 70% of cervical cancer cases and may also play a role in the development of other types of cancer <ref>[http://www.cancer.gov/cancertopics/factsheet/Risk/HPV]</ref>. In June 2006, the U.S. Food and Drug Administration approved the first HPV vaccine based on observance of elevated [[antibody]] levels in a few thousand patients who had received the vaccine (including perhaps only a few hundred or less young girls).

The HPV vaccine does not protect against other sexually transmitted diseases (e.g., chlamydia, herpes, hepatitis, trichomoniasis, gonorrhea, syphilis, HIV, AIDS, etc.).  The vaccine is not recommended for use in pregnant women or girls.{{fact}}

The HPV vaccine does not protect against other sexually transmitted diseases (e.g., chlamydia, herpes, hepatitis, trichomoniasis, gonorrhea, syphilis, [[HIV]], [[AIDS]], etc.).  The vaccine is not recommended for use in pregnant women or girls.{{fact}}

The long-term consequences of the HPV vaccine are not known and there have not been any long-term studies.  Children in the 9-year-old age group have been monitored for only 18 months, and there have been no studies on the carcinogenic risk or the general toxicity of the vaccine itself.  Between July 2006 and January 2007, there were 82 reports of adverse events filed with the Vaccine Adverse Event Reporting System ([[VAERS]]) following the receipt of the vaccine.

The long-term consequences of the HPV vaccine are not known and there have not been any long-term studies.  Children in the 9-year-old age group have been monitored for only 18 months, and there have been no studies on the carcinogenic risk or the general toxicity of the vaccine itself.  Between July 2006 and January 2007, there were 82 reports of adverse events filed with the Vaccine Adverse Event Reporting System ([[VAERS]]) following the receipt of the vaccine.